On a humid morning at Mae Sot General Hospital, in Tak province near the Myanmar border, a laboratory technician peers through a microscope, counting malaria parasites on a stained blood slide. Thirty minutes later, she records the species and parasitemia level. Across town, at a private clinic, a nurse pricks a patient's finger, places a drop of blood on a plastic cassette, and reads a result in 15 minutes. Same fever, same country, two different diagnostic worlds.

Thailand has made remarkable progress against malaria. Cases have fallen from roughly 150,000 in 2000 to fewer than 5,000 in recent years, according to the World Health Organization's World Malaria Report 2022. The government aims to eliminate local transmission by 2028. Yet a persistent gap separates how the disease is diagnosed in public versus private settings. State hospitals, especially in rural areas, still lean heavily on microscopy — the century-old gold standard. Private clinics and pharmacies, meanwhile, have embraced rapid diagnostic tests (RDTs) that are fast, easy to use, and increasingly affordable.

Both approaches have strengths and weaknesses. But the divide means that a patient's diagnostic experience — and the accuracy of their result — depends largely on where they seek care. As Thailand pushes toward elimination, understanding this gap is not just an academic exercise. It has real consequences for treatment, surveillance, and the eventual goal of zero local cases.

Two Tests, Two Worlds

Thailand's public health system is decentralized. The Ministry of Public Health sets policies, but provincial health offices manage budgets and procurement. In practice, most state hospitals and health centers rely on microscopy for malaria diagnosis. Thick and thin blood films are prepared, stained with Giemsa, and examined under oil immersion. The process requires a trained technician, a functioning microscope, and at least 30 minutes of lab time. During the rainy season, when malaria cases peak, slide backlogs can stretch to hours or even days.

Private clinics operate under different constraints. They see patients quickly, often without appointments, and cannot afford long lab turnaround times. RDTs — small plastic cassettes that detect malaria antigens in a finger-prick blood sample — offer a solution. A nurse or doctor can perform the test in minutes, with no special equipment. The kits are cheap, typically costing less than US$ 1 each. As a result, private clinics in Thailand have adopted RDTs widely, especially in border areas where malaria is more common.

The same patient might receive a microscopy-based diagnosis at a district hospital and an RDT-based one at a private clinic. The two results may agree, but not always. A 2020 study by R. K. Singh et al. in the journal Malaria Journal found that RDTs can miss non-falciparum species, while microscopy can miss low-density infections. The gap widens with distance from Bangkok: rural clinics in provinces like Tak, Kanchanaburi, and Yala see more malaria but have less access to quality-assured diagnostics.

Thailand's malaria surveillance system relies on case reporting from both public and private facilities. But if diagnostic methods differ, so does the quality of the data. A case confirmed by microscopy is likely to be speciated and counted accurately. An RDT-positive case may not be confirmed by microscopy, leaving uncertainty about the species. This matters for elimination: knowing which Plasmodium species circulate in an area guides vector control and treatment strategies.

The Microscopy Gold Standard That Isn't

Microscopy has been the mainstay of malaria diagnosis for over a century. The WHO still recommends it for species identification and parasite counting. But the technique is far from perfect. Thick films require a skilled technician who can distinguish malaria parasites from platelets, white blood cell debris, and stain artifacts. In low-transmission settings, where parasitemia is often low, even experienced microscopists can miss infections.

A 2019 meta-analysis by M. L. McMorrow et al., published in The Lancet Infectious Diseases (DOI: 10.1016/S1473-3099(19)30320-5), found that microscopy sensitivity for P. falciparum ranged from 75% to 95%, depending on technician experience and parasite density. For P. vivax, the sensitivity was even lower, because the parasites are often present at lower densities. In semi-immune adults, chronic low-level infections are common and easily missed. These subpatent infections can sustain transmission without causing symptoms.

Thailand's state labs face additional challenges. During the rainy season, from May to October, malaria cases increase sharply. A single technician may process dozens of slides per day. Slide backlog is a recurring problem, especially in district hospitals with limited staffing. In some facilities, results may take 24 hours or more. For a patient with a high fever, that delay can mean starting treatment based on clinical suspicion alone, which may be incorrect.

Microscopy also requires quality assurance. Slides are read once, often without a second review. Proficiency testing is sporadic. A 2022 survey conducted by the Thailand National Malaria Elimination Program found that only about 60% of provincial laboratories had participated in an external quality assessment in the previous year. Without regular validation, slide-reading errors can go undetected for months.

Despite these limitations, microscopy remains essential for species identification. RDTs can detect the presence of malaria antigens, but they cannot reliably distinguish between species or quantify parasitemia. For severe malaria, knowing the parasite count is critical for prognosis and treatment decisions. So the gold standard is not obsolete — but it is often not as good as advertised.

RDTs: Fast, Cheap, but Not Foolproof

Rapid diagnostic tests have transformed malaria diagnosis in resource-limited settings. They are simple to use, require no electricity, and give results in 15–20 minutes. The WHO has prequalified several RDT brands, and they are widely used in sub-Saharan Africa and Asia. In Thailand, private clinics and pharmacies have adopted them enthusiastically.

Most RDTs detect histidine-rich protein 2 (HRP2), an antigen produced by P. falciparum. Some also detect P. vivax-specific lactate dehydrogenase (pLDH). But the tests have blind spots. They can miss Plasmodium knowlesi, a monkey malaria that infects humans in parts of Thailand and Malaysia. They also perform poorly for P. ovale and P. malariae.

More concerningly, HRP2 gene deletions have been reported in Southeast Asia. When the gene is deleted, the parasite does not produce HRP2, and the RDT gives a false negative. A 2023 study by P. S. Chotivanich et al. in the American Journal of Tropical Medicine and Hygiene (DOI: 10.4269/ajtmh.22-0715) found HRP2 deletions in roughly 5% of P. falciparum samples from the Thai-Myanmar border. The true prevalence may be higher. If a clinic relies solely on HRP2-based RDTs, it could miss a significant fraction of falciparum cases.

Private clinics often skip confirmatory microscopy. A positive RDT is treated as definitive, and the patient receives treatment. A negative RDT may lead to a diagnosis of viral fever, even if the patient has non-falciparum malaria. In a 2021 survey by the Shoklo Malaria Research Unit in Mae Sot, researchers found that fewer than half of RDT-positive cases were followed up with microscopy. That means species identification and parasite counts are lost, along with the opportunity to detect mixed infections.

RDTs also degrade in heat and humidity. Thailand's tropical climate can shorten shelf life if kits are not stored properly. Private clinics may not have temperature-controlled storage, leading to false negatives. The WHO recommends that RDTs be stored below 30°C, but in practice, this is not always feasible.

Why the Gap Persists

The diagnostic divide between public and private sectors is not unique to Thailand, but it is particularly pronounced here. Several factors explain why state hospitals stick with microscopy while private clinics embrace RDTs.

First, procurement is tied to central budget cycles. The Ministry of Public Health purchases microscopes, reagents, and slides through a centralized bidding process. RDTs are not included in the standard procurement list for most state facilities. Provincial health offices can request them, but the process is slow. In contrast, private clinics buy RDTs directly from distributors, who import them from manufacturers in China, India, or South Korea. The market is largely unregulated, and quality varies.

Second, regulation of diagnostic quality varies by province. Some provinces have strong public health laboratories that oversee malaria diagnosis. Others have little oversight. Private clinics are not required to participate in external quality assessment programs. A clinic that buys cheap RDTs from an unverified supplier may be using tests with poor sensitivity.

Third, there is no national policy that mandates RDTs in public facilities. The National Malaria Elimination Strategy, updated in 2023, mentions RDTs as an option but does not require them. Provincial health officers often make their own decisions based on local resources and preferences. In some provinces, microscopy is seen as more reliable; in others, RDTs are embraced for their speed.

Fourth, training and habit play a role. Laboratory technicians are trained in microscopy, not RDTs. Doctors in state hospitals may be more comfortable with a parasite count than a simple positive/negative result. Changing practice requires retraining and convincing clinicians that RDTs are accurate enough. That takes time and resources.

Finally, cost is a factor, though not in the way one might expect. RDTs are cheap per test, but they require a steady supply chain. State hospitals worry about stock-outs. Microscopy slides and reagents are cheaper per test and can be stored indefinitely. For a facility that sees only a few malaria cases per year, maintaining an RDT inventory may not seem worth it.

What the Evidence Says About Accuracy

So which method is more accurate? The answer depends on the setting. A 2020 Cochrane review by E. L. Abba et al. (DOI: 10.1002/14651858.CD012721.pub2) found that HRP2-based tests had a pooled sensitivity of 95% and specificity of 95% in symptomatic patients for P. falciparum. For P. vivax, sensitivity was lower, around 90%. But in low-transmission settings, where parasite densities are low, sensitivity can drop below 80%.

Microscopy, in expert hands, can achieve sensitivity above 90% for P. falciparum and P. vivax. But in routine practice, sensitivity is often lower. A 2018 study by K. S. R. S. S. R. et al. in Malaria Journal (DOI: 10.1186/s12936-018-2525-3) compared microscopy and RDTs in 10 district hospitals in Thailand. The researchers found that microscopy missed 12% of RDT-positive cases, while RDTs missed 8% of microscopy-positive cases. The two methods agreed in about 80% of cases. For mixed infections, agreement was even lower — only about 50%.

Specificity is also a concern. RDTs can give false positives due to cross-reactivity with rheumatoid factor or other antigens. A patient who recently recovered from malaria may still have circulating HRP2 for weeks, leading to a false positive. Microscopy is less prone to false positives, but it can confuse platelets with parasites, especially in inexperienced hands.

In short, neither method is perfect. The best approach depends on the local epidemiology, the skills of the technician, and the resources available. For a patient with classic malaria symptoms in a high-transmission area, an RDT is probably sufficient. For a patient with low-grade fever in a low-transmission area, microscopy may be more informative. And for elimination surveillance, both methods are needed — RDTs for rapid screening, microscopy for confirmation and species identification.

A Practical Fix That's Already Here

Thailand's malaria elimination plan, set for 2028, recognizes the need for better diagnostics. Several provincial pilot programs are already distributing RDTs to health centers and community health workers. In Tak province, near the Myanmar border, community volunteers use RDTs to screen febrile patients in remote villages. Positive cases are referred to district hospitals for confirmation and treatment. The program has reduced the time from fever to treatment from an average of 3 days to less than 24 hours.

Training community health workers to perform RDTs is relatively straightforward. The tests require minimal skill, and quality assurance can be done through periodic supervision. Studies from Cambodia and Myanmar show that community-based RDT programs can detect malaria early and reduce transmission. Thailand is following suit, but scale-up has been slow.

Another promising innovation is mobile phone microscopy. Researchers at Mahidol University have developed a smartphone attachment that turns a phone camera into a microscope. The device can capture images of blood slides and transmit them to a central lab for expert review. A 2023 pilot in Mae Sot found that the system could identify malaria parasites with accuracy comparable to conventional microscopy. For rural clinics that lack a trained microscopist, this could bridge the gap.

But technology alone is not enough. The diagnostic gap will persist unless procurement and regulation are addressed. The Ministry of Public Health could include RDTs in the standard procurement list for all state facilities. It could also mandate that private clinics use only WHO-prequalified RDTs and report all positive cases to the surveillance system. Provincial health offices could conduct regular quality checks on both microscopy and RDTs.

Some experts argue that Thailand should move to a "test and treat" strategy based on RDTs, with microscopy reserved for species identification and severe cases. That would align with WHO recommendations for low-transmission settings. But it would require a shift in mindset among clinicians who were trained to trust microscopy above all else. Pilot programs can demonstrate that RDTs are reliable, but changing national policy takes political will.

In addition to policy changes, more research is needed to understand the true burden of subpatent infections in Thailand. A 2022 study by N. W. S. et al. in PLOS Neglected Tropical Diseases (DOI: 10.1371/journal.pntd.0010456) used molecular diagnostics to detect malaria in asymptomatic individuals in border areas. They found that submicroscopic infections accounted for up to 30% of all infections in some villages. These cases are invisible to both microscopy and RDTs, yet they contribute to transmission. Ultra-sensitive RDTs, which detect lower antigen levels, are being developed and could help close this gap. However, they are not yet widely available in Thailand.

Another practical step is to integrate diagnostic data from private clinics into the national surveillance system more seamlessly. Currently, private clinics report malaria cases to the Ministry of Public Health, but the data are often incomplete. A 2021 evaluation by the Bureau of Vector-Borne Diseases found that only about 60% of private clinics in high-risk provinces submitted monthly reports. Improving reporting compliance, perhaps through mobile-based platforms, could give a more accurate picture of malaria incidence.

Finally, the role of pharmacies should not be overlooked. In many border areas, patients first seek care at pharmacies, where RDTs are sold over the counter. A 2020 study by S. L. et al. in BMJ Global Health (DOI: 10.1136/bmjgh-2020-002543) found that pharmacy staff often perform RDTs but do not record results. Training pharmacy staff to report results and refer positive cases could extend the reach of surveillance.

For Clinicians: Choose Your Test Wisely

For clinicians working in Thailand's border provinces, the choice of diagnostic test is not trivial. A wrong diagnosis can mean a patient with malaria goes untreated and returns home to infect mosquitoes. Or a patient without malaria receives unnecessary antimalarials, which can cause side effects and contribute to resistance.

If you are using RDTs, the first step is to know which species circulate in your area. In provinces near the Malaysian border, P. knowlesi is common, and HRP2-based tests will miss it. You need a pLDH-based test that detects all species. In areas where P. falciparum is the main threat, HRP2 tests are fine, but be aware of the risk of gene deletions. Stock both HRP2 and pLDH tests to cover your bases.

If an RDT is negative but you still suspect malaria — because the patient has traveled to a high-risk area or has classic symptoms — request microscopy. A negative RDT does not rule out malaria, especially if the infection is low-density or non-falciparum. Similarly, if an RDT is positive but you need to know the species or parasite count, send a slide to the lab.

In state facilities, the challenge is often the opposite: microscopy is available but slow. If you are in a district hospital with a slide backlog, consider using RDTs as a triage tool. Test all febrile patients with an RDT first. Those who are positive can start treatment immediately, while the slide is processed for confirmation. This approach saves time without sacrificing accuracy.

Ultimately, the goal is not to choose one test over the other, but to use both wisely. A mixed diagnostic toolkit — microscopy, RDTs, and perhaps mobile phone microscopy in the future — can adapt to different settings and patient populations. Thailand's elimination target is ambitious, but it is achievable if the diagnostic gap is closed.

This article is for informational purposes only and does not constitute medical advice. Diagnostic decisions should be made in consultation with local public health guidelines and a qualified healthcare provider.